Symbiotec Pharmalab IPO

Strengths · 8

• 01The company is a global leader in corticosteroid and steroidal hormone APIs, which is a specialised area with few makers worldwide.
• 02Its plants carry approvals from the US FDA, EU-GMP and the Korean drug regulator, which are hard to get and act as an entry barrier.
• 03Sales have grown every year, from Rs 723.33 crore in FY2024 to Rs 755.98 crore in FY2025 and Rs 872.26 crore in FY2026.
• 04EBITDA has improved steadily, from Rs 177.04 crore in FY2024 to Rs 206.11 crore in FY2025 and Rs 231.97 crore in FY2026.
• 05Borrowing was reduced sharply in the last year, from Rs 540.92 crore to Rs 387.91 crore, while net worth rose from Rs 821.15 crore to Rs 1,158.64 crore.
• 06The company is backward integrated and runs at industrial scale, with chemical synthesis capacity of 584.67 metric tonnes and fermentation capacity of 300 kilolitres.
• 07It has more than 30 years of experience in this line, having started as a lab scale steroid API maker in 1995.
• 08It sells into both regulated markets such as the USA and Europe and into emerging markets, so demand is not tied to one region.

Risks · 8

• 01This is by far the most expensive issue in the current batch on earnings. At the upper band of Rs 988 the P/E is about 56.81 times on an EPS of Rs 17.39.
• 02Return ratios are low for that valuation. RoCE was 11.80% and RoNW was 11.79%.
• 03Profit has been almost flat for three years, at Rs 100.06 crore in FY2024, Rs 96.79 crore in FY2025 and Rs 109.90 crore in FY2026, even though assets grew from Rs 1,294.79 crore to Rs 1,780.79 crore over the same period.
• 04Very little of the issue money reaches the company. The stated objects account for only Rs 112.50 crore of borrowing repayment plus general corporate purposes, against a total issue of Rs 1,757 crore, which indicates that most of the issue is an offer for sale by existing shareholders.
• 05The pre issue and post issue promoter holding is not stated in the available data, so the extent of promoter dilution is not clear.
• 06API making is a regulated business. A negative inspection by the US FDA or the EU authorities at either plant can stop supply to those markets.
• 07The company is concentrated in steroid and corticosteroid APIs. A price fall or new capacity in that narrow segment would hit it directly.
• 08Borrowing is still sizeable at Rs 387.91 crore, and it had risen to Rs 540.92 crore in FY2025 before coming down, so the debt level has moved around a lot.

Symbiotec Pharmalab Ltd was set up in 2002. It is a pharmaceutical and biotechnology company that develops and makes active pharmaceutical ingredients, known as APIs, along with nutritional ingredients and specialty products. APIs are the actual medicine content that goes into a tablet or injection, which other pharma companies then turn into finished medicines.

The company started in 1995 as a small lab scale maker of steroidal hormone APIs and has grown into a large backward integrated manufacturer with more than 30 years of experience in the field. It is a global leader in corticosteroid and steroidal hormone APIs.

Its plants are approved by the United States Food and Drug Administration, by European Union Good Manufacturing Practices and by the Ministry of Food and Drug Safety of Korea, among other regulators. As on 30 June 2025 it ran two industrial scale API plants with a chemical synthesis capacity of 584.67 metric tonnes and a fermentation capacity of 300 kilolitres. It sells both in India and abroad, in regulated as well as emerging markets.

Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.